|Home Page : www.otcjournal.com
Email Questions or Comments To: email@example.com
OTC Journal Members:
Winner #4 in the last 30 days should be dished up post open today, and I couldn't be more excited about the way things are going. In case you haven't been paying attention of late, here's three stocks I've been covering that have dished you up monster profits if you invested recently:
I know these gains seem extraordinary, and they are. I know there have also been a few losers sprinkled in over that time frame, and there have been. However, these are real returns, and you can just click on the dates, read the original editions, and look at where the stocks are now.
That's really good news, but there's great news today as well. I'm as near as certain as I can be that I'll be adding a 4th recent idea to that extraordinary list based on the pre-open news from one of the other followings.
Please tell me you already own this one. If not, it's probably not too late. I don't know where the stock will open or even if it will open a lot higher than Friday's close. However, today's news turns the Plandai (OTC BB: PLPL) dream into a reality, and I suspect the stock is poised to rock.
Read on- only if you like making money....
Lest you think the health food sector has not been hot of late, consider the following:
So, lest you think this sector is not smoking hot- just look at those numbers and I believe you'll see it differently.
Identifying the up and coming small stocks in a hot sector can yield remarkable returns.
Today, before the market opened, Plandai Biotech (PLPL)- a stock I featured back on March 26th, announced a watershed event and one that I am very certain will add PLPL to the big winners list featured in the first section.
Rather than a full review of what the company does, I'll simply reference my initial presentation if you want all the details. The March 26th edition tells you all you need to know. The stock was $.25 that day, and closed at $.28 on Friday- so there's still plenty of upside.
The quick over view- Plandai (PLPL) is a combination agricultural/biotech technology company. The company's founders have developed a revolutionary new technique for super charging Green Tea Extract- a food product in huge demand. Rather than license, they plan to grow tea, process extract, and sell it to major beverage companies to maximize their profit potential.
Today, before the market opened, the PLPL horses left the gate. The company has a 49 year lease on 8500 acres in prime South African tea growing country, but needed money to start growing and to build their processing plant.
Today, PLPL disclosed it had finally gotten the long awaited 100 million Rand ($13 Million US dollars) low cost loan from the South African Land Bank- an agency of the South African government.
The terms of the loan are remarkable- they pay .5% interest- yes, that's 1/2 percent. They don't have to make a payment for 25 months. It's secured by the assets of the company and agricultural receivables. One subsidiary must share 15% of profits somewhere down the road.
At $.27, the stock reflected a company with interesting and exciting technology, but no money to implement its strategies.
This is a resounding endorsement of the company from the South African government. Land must be cleared, tea must be grown, and production equipment must be acquired, assembled, and producing.
Can you imagine owning this stock somewhere down the road when they start getting purchase orders from major international names in the healthy beverage industry?
You're getting this information on PLPL before anyone. The company has filed this information with the SEC, but hasn't put out a formal press release yet. I'm sure that's to follow.
By the time you read this, I have no idea where the stock will be trading. If the market hasn't jumped on it, you might be able to acquire shares at $.30 or under.
Here's what I know. The company announced this funding from the South African government in January, and the stock ran up to $.60. Then there were complications, and it took 3 more months to close the transaction.
A return to $.60 would be a cool double from Friday's levels. Regardless of what happens in reaction to the news in the short term, I am certain PLPL will now join the ranks of the big wins listed in the first section of today's edition.
Much more to come on PLPL.
I'll be featuring Plandai (PLPL) on today's BigBizShow at about 12:30PM Eastern, 9:30 AM Pacific. Tune in.
The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.
All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.